Biotech Startups

Kula Bio develops bacterial propagation and feeding systems that enhance the nitrogen-fixing capabilities of naturally occurring microbes for agricultural applications. The company applies microbial technology originally derived from bionic leaf research to improve crop and turf production.

7 investors

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection. Its platforms serve cell therapy researchers and developers, supporting drug discovery, process optimization, and scaling from small-volume experiments to manufacturing.

7 investors

Level Zero Health develops electrochemical and microfluidic biosensor platforms for point-of-care and continuous diagnostic devices. The company serves healthcare providers and patients requiring faster, more accessible diagnostic solutions.

7 investors

Mediartx develops novel therapies for patients with fibrotic diseases.

7 investors

Mercy develops blood-based tests for early cancer detection using its patented Mercy Halo platform, which applies qPCR technology and extracellular vesicles to identify combinations of cancer-associated biomarkers. The company aims to provide low-cost, broadly accessible diagnostics that detect cancer at its earliest, most treatable stages.

7 investors

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG). It uses a "search & development" strategy to identify and advance drug programs for specific patient populations.

7 investors

MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus, with a lead candidate (AlpN GBS) in clinical trials for use in pregnancy and older adults. Its vaccine aims to prevent adverse pregnancy outcomes and life-threatening infections caused by Group B Streptococcus.

7 investors

Minoryx is a biopharmaceutical company that discovers and develops drug treatments for severe orphan diseases of the central nervous system, such as cerebral adrenoleukodystrophy and Rett syndrome. Its lead candidate, leriglitazone, is being evaluated in clinical trials and regulatory review for these rare CNS conditions.

7 investors

Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.

7 investors

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

7 investors

ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness. Its lead candidate, xelafaslatide (formerly ONL1204), is a first-in-class small peptide targeting Fas-mediated signaling across multiple eye diseases.

7 investors

Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.

7 investors

ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

7 investors

Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections. Its lead candidate is in a pivotal Phase 2/3 trial and holds FDA Orphan Disease, Fast Track, and QIDP designations.

7 investors

Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.

7 investors

Probably Genetic operates a platform for diagnosing genetic diseases, providing comprehensive genetic data and testing to patients and healthcare providers. The company works with patient advocacy groups to connect patients with genetic conditions to diagnostic services and community support.

7 investors

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.

7 investors

RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.

7 investors

Rubedo Life Sciences develops therapeutics targeting aging by eliminating senescent cells to extend human healthspan. The company applies artificial intelligence and chemistry to drug discovery in the longevity and regenerative medicine space.

7 investors

Scipher Medicine is a precision immunology company that combines molecular data from autoimmune patients, protein interaction mapping, and AI to match patients with the most effective therapy for immunological diseases. Its offerings support therapy selection based on biomarkers and assist drug developers with research insights and commercialization analytics.

7 investors

Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.

7 investors

Siren Biotechnology develops next-generation AAV (adeno-associated virus) platforms for gene therapy applications, including gene repair, gene transfer, and gene editing. The company focuses on advancing treatments for a wide range of rare diseases through engineered viral vectors and directed evolution approaches.

7 investors

Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases. The company focuses on non-viral delivery methods to enable potentially curative genetic therapies.

7 investors

TetraScience provides a Scientific Data and AI Platform that produces AI-native scientific data and lab data management products for scientific research and discovery. The platform serves life sciences organizations seeking to accelerate scientific outcomes through collaborative data infrastructure and AI applications.

7 investors